newsfilter
← Latest News
Business Wire·

Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Clinical programs advancing in rare hematologic diseases and cancers May 26 R&D Day to focus on research pipeline strategy and expanded development programs Cash balance of $441.3 million positions company with runway through the third quarter of